BC
IMGN

Barrett & Company’s Immunogen Inc IMGN Stock Holding History

Barrett & Company’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,000
Closed -$23K – 619
2023
Q1 		$23K Hold
6,000
– – 0.01% 311
2022
Q4 		$29.8K Hold
6,000
– – 0.02% 274
2022
Q3 		$29.8K Buy
+6,000
New +$31.6K 0.02% 274

Other funds holding IMGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrett & Company's IMGN Position: Q2 2023 in Review

Barrett & Company sold out of Immunogen Inc (IMGN) in Q2 2023, closing a stake of 6,000 shares — an estimated $23K sold.

Barrett & Company first reported a position in IMGN in Q3 2022 and held it in 3 quarters. The position peaked at $29.8K in Q4 2022. 266 funds tracked by Wall St. Rank hold IMGN as of Q2 2023.

  • Barrett & Company reported no remaining Immunogen Inc position as of Q2 2023 after selling out during the quarter.
  • Barrett & Company sold 6,000 Immunogen Inc shares in Q2 2023, an estimated $23K.
  • Barrett & Company first reported a position in Immunogen Inc in Q3 2022 and held it in 3 quarters.
  • Barrett & Company's Immunogen Inc position peaked at $29.8K in Q4 2022.
  • 266 funds tracked by Wall St. Rank held Immunogen Inc as of Q2 2023.

Based on Barrett & Company's 13F filing for Q2 2023, filed 27 Jul 2023.